Literature DB >> 12842981

VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.

Dirk Kienle1, Alexander Kröber, Tiemo Katzenberger, German Ott, Elke Leupolt, Thomas F E Barth, Peter Möller, Axel Benner, Annett Habermann, Hans Konrad Müller-Hermelink, Martin Bentz, Peter Lichter, Hartmut Dōhner, Stephan Stilgenbauer.   

Abstract

Immunoglobulin variable heavy chain gene (VH) mutation status and VDJ rearrangement structure were analyzed in 141 patients with mantle cell lymphoma (MCL) and correlated with biologic and clinical characteristics; 29% of the MCLs displayed mutated VH using a 98% germline homology cutoff. Striking differences occurred in the VH mutation subgroups with respect to the use of specific V genes. Rearrangements involving V4-34 and V3-21 were almost exclusively unmutated, whereas rearrangements using V4-59 and V3-23 were typically mutated. Significant association occurred between mutated VH with shorter CDR3 lengths and the use of JH4b. V3-21 and V4-59 were involved in highly characteristic rearrangements, implying that antigen specificity might have been involved in MCL development. There was no evidence for isotype switch recombination or Bcl-6 expression in any MCL. ZAP70 expression was not different in VH-mutated or -unmutated MCL. Although the deletions 11q- and 17p- showed a balanced distribution, an overrepresentation was observed for trisomies +3q, +8q, and tetraploidy in the VH-unmutated subgroup and +12q in the VH-mutated subgroup. Clinically, mutated VH was associated with a higher rate of complete remission, but there was no correlation between VH mutation status and other clinical characteristics or overall survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842981     DOI: 10.1182/blood-2003-05-1383

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

Review 1.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

2.  CD5+ diffuse large B-cell lymphoma consists of germline cases and hypermutated cases in the immunoglobulin heavy chain gene variable region.

Authors:  Naoya Nakamura; Shigeo Nakamura; Motoko Yamaguchi; Ryo Ichinohasama; Tadashi Yoshino; Tetsuo Kuze; Yoshikazu Sasaki; Sachiko Yoshida; Masafumi Abe
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

3.  Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells.

Authors:  Laurent D Vallat; Yuhyun Park; Cheng Li; John G Gribben
Journal:  Blood       Date:  2007-01-18       Impact factor: 22.113

Review 4.  Mantle cell lymphoma: evolving novel options.

Authors:  Andre Goy
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

5.  Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice.

Authors:  Ek Sara; Carl Ak Borrebaeck
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

6.  Indolent mantle cell lymphoma.

Authors:  Michelle Furtado; Simon Rule
Journal:  Haematologica       Date:  2011-08       Impact factor: 9.941

7.  T(11;18)(q21;q21)-positive gastrointestinal MALT lymphomas are heterogeneous with respect to the V(H) gene mutation status.

Authors:  Xavier Sagaert; Brigitte Maes; Vera Vanhentenrijk; Mathijs Baens; Eric Van Cutsem; Gert De Hertogh; Karel Geboes; Thomas Tousseyn
Journal:  World J Gastrointest Oncol       Date:  2011-02-15

8.  Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.

Authors:  Simone Ferrero; Daniela Capello; Mirija Svaldi; Michela Boi; Daniela Gatti; Daniela Drandi; Davide Rossi; Sara Barbiero; Barbara Mantoan; Elisabetta Mantella; Manuela Zanni; Paola Ghione; Alessandra Larocca; Roberto Passera; Francesco Bertoni; Valter Gattei; Francesco Forconi; Luca Laurenti; Giovanni Del Poeta; Roberto Marasca; Sergio Cortelazzo; Gianluca Gaidano; Antonio Palumbo; Mario Boccadoro; Marco Ladetto
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

Review 9.  Molecular pathogenesis of mantle cell lymphoma.

Authors:  Pedro Jares; Dolors Colomer; Elias Campo
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 10.  Why does cytotoxic chemotherapy cure only some cancers?

Authors:  Philip Savage; Justin Stebbing; Mark Bower; Tim Crook
Journal:  Nat Clin Pract Oncol       Date:  2008-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.